Carnosine in the treatment of Autism
Not Applicable
- Conditions
- Autistic Disorder.Childhood autism
- Registration Number
- IRCT201512081556N83
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Inclusion Criteria: 1-DSM-5 clinical diagnosis of autistic disorder, 2-children between the ages of 3 and 12 years ,3- presence of behavioral problems such as aggression, overactivity or repetitive behaviors (indication of treatment with risperidone)
Exclusion Criteria
1- Presence of any active medical problem, 2-any diagnosis in Axis I and II except for mental retardation, 3- receiving any psychotropic medications during past two weeks prior to the trial, 5-presence of hepatic disease, 6-history of seizure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of Autism. Timepoint: Baseline and weeks 5 and 10 after begining of treatment. Method of measurement: Aberrant Behavior Checklist-Community (ABC-C) Rating Scale (Irritability subscale ).
- Secondary Outcome Measures
Name Time Method